Cartalax 20mg (Bioregulator)

Amino Acid Sequence: Ala-Glu-Asp (AED)
Molecular Formula: C₁₂H₁₉N₃O₈
Molecular Weight: 333.29 g/mol
PubChem CID: 87815447
Synonyms: T-31, AED, SCHEMBL5324601, Alanyl-glutamyl-aspartic acid

Source: PubChem

Cartalax is supplied exclusively for research use in laboratory settings. Reported experimental applications include in-vitro and in-vivo animal studies examining fibroblast-associated signaling, extracellular matrix regulation, and transcriptional responses. Typical research applications include: (i) cellular proliferation and apoptosis assays using fibroblast cultures; (ii) analysis of matrix metalloproteinase (MMP) expression and extracellular matrix turnover; (iii) investigation of transcription factor activity (e.g., NF-κB, AP-1) under experimentally induced stress conditions; and (iv) renal and connective-tissue cell culture models used to evaluate peptide-associated modulation of senescence-linked molecular markers.

Mechanistic studies of Cartalax emphasize its interaction with intracellular regulatory pathways common to fibroblast biology. Reported experimental observations include modulation of proliferation-associated markers such as Ki-67, altered signaling through transcription factors including NF-κB and AP-1, and changes in apoptosis-related proteins such as p53 and caspase-associated pathways. These effects are evaluated in the context of transcriptional regulation, chromatin accessibility, and downstream gene-expression programs.

Additional studies examine the influence of Cartalax on extracellular matrix remodeling through regulation of matrix metalloproteinases (including MMP-1, MMP-3, MMP-8, and MMP-9) and associated signaling mediators (e.g., TGF-β, TNF-α, CCN1). In these models, peptide-associated effects are interpreted as shifts in the balance of matrix synthesis and degradation within defined experimental systems rather than as outcome-driven biological responses.

Renal cell culture investigations further describe Cartalax-associated modulation of senescence-linked molecular markers, including altered expression of p16, p21, p53, and sirtuin-family proteins such as SIRT-6. These pathways are analyzed in vitro to characterize peptide-associated changes in transcriptional and epigenetic regulation during cellular aging models.

Preclinical research on Cartalax includes fibroblast-based in-vitro studies and animal-derived tissue culture models. Skin-associated fibroblast experiments report peptide-associated changes in proliferation indices, apoptosis markers, and extracellular matrix–related gene expression under controlled laboratory conditions. These studies are frequently conducted using aging or stress-induced cellular models to evaluate transcriptional and biochemical responses.

Additional preclinical investigations involve renal tissue cultures from young and aged animals, where Cartalax is evaluated alongside other short peptides for its influence on cell renewal markers and senescence-associated proteins. Across these studies, findings are reported as experimental observations within defined model systems and are used to support mechanistic hypotheses related to peptide-mediated regulation of fibroblast and renal cell biology.

This product is provided strictly as a laboratory research reagent. Standard analytical characterization for short peptides may include chromatographic purity analysis (e.g., HPLC or UPLC) and molecular mass confirmation by mass spectrometry. Researchers should consult lot-specific certificates of analysis (COA) for identity, purity, and analytical data relevant to experimental documentation and quality assurance.